Skip to main content
Premium Trial:

Request an Annual Quote

Chinese Firm Builds Genomics Facility for Translational Research with PacBio as Major Platform


NEW YORK (GenomeWeb) − The Suqian Lakeside Pangu Gene Company in Tianjin, China, has established a new genomics facility for translational medicine research projects.

The company plans to focus on molecular-based approaches for the early diagnosis of cancer and disease recurrence, and on drug efficacy evaluation.

The new facility, located in the Tianjin Dong Li Lake Technology Park, has 1,500 square meters of lab space and will be using Pacific Biosciences' PacBio RS II as its major sequencing platform, the two firms said this week. Earlier this year, SLPC purchased four PacBio RS II systems, which were recently installed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.